
|Videos|September 3, 2014
Lean Body Mass as a Clinical Outcome in Multicentric Castleman’s Disease
Author(s)Michael Sawyer, MD
Michael Sawyer, MD, associate professor, Medical Oncology, University of Alberta, discusses lean body mass as a clinical outcome in multicentric Castleman’s disease.
Advertisement
Clinical Pearls
Michael Sawyer, MD, associate professor, Medical Oncology, University of Alberta, discusses lean body mass as a clinical outcome in multicentric Castleman’s disease.
- Lean body mass is an important clinical outcome because it appears to be related to frailty in other literatures.
- The hope is to eventually study the relationship between fatigue, function, and lean body mass in patients on siltuximab.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5








































